A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

NCT03944057 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapse/Refractory Multiple Myeloma

Interventions

DRUG: ATG-010

Sponsor

Antengene Corporation